Schering Results Miss Targets
251914
The disappointing resuslts sent shares down more than 10 percent amid concerns about its flagship cholesterol drugs.
205867
German drug maker Schering, recently acquired by pharmaceuticals and chemicals giant Bayer, has said that it was teaming up with British drug giant AstraZeneca to develop a new treatment against breast cancer.
33756
Schering-Plough Corp and Merck & Co are defending their shared cholesterol treatments, Vytorin and Zetia, in advertisements after a failed study generated negative publicity.
677326
BASEL, Switzerland  - Swiss drugmaker Novartis AG  missed forecasts with a 42 percent drop in fourth-quarter net profit, hit by generic competition and a one-off restructuring charge, sending its shares lower.
310098
Schering-Plough Corp.  on Monday said quarterly earnings more than doubled on growing demand for its Zetia and Vytorin cholesterol drugs and its treatments for arthritis and allergies.
414190
FRANKFURT/CHICAGO  - U.S. regulators have demanded  more clinical studies of a new substance designed to produce  clearer MRI pictures of clogged arteries, Germany's Schering AG  and U.S. partner Epix Pharmaceuticals Inc. said on Friday.
594500
Schering-Plough Corp. SGP.N on  Thursday reported a quarterly profit after a year-ago loss, as  positive foreign exchange trends helped offset poor sales of  its allergy and hepatitis drugs.
730824
Charges hurt the quarterly results of Johnson & Johnson, Merck & Co. and Schering-Plough Corp., but the drugmakers' shares rose as J&J's earnings beat Wall Street forecasts and Merck sales edged higher despite the withdrawal of its best-selling Vioxx arthritis drug.
59608
Standard &amp; Poor&#39;s Equity Research reiterated a &quot;hold&quot; rating and $68 target price on Biogen Idec (nasdaq: BIIB - news - people ), saying the anticipated success of the company&#39;s Antegren drug is largely factored into the share price.
575659
Forest Laboratories Inc. (FRX) on Tuesday said its experimental hypertension drug failed to meet all its goals in an effectiveness study, an outcome that will delay development and may lead to a new trial.
746919
Drug maker Schering-Plough Corp   on Tuesday reported a fourth-quarter loss as special  charges from its acquisition of Organon Biosciences late last  year offset sharply higher sales.
140996
A day late and possibly several millions of dollars short. That's the scenario facing one drug manufacturer unless it can get a helping hand from Congress.
161495
Progress on its lead drug remains stalled.
472694
Novartis AG lowered its full-year results outlook as generic competition pressured sales of a key blood-pressure drug, and said U.S. regulators had delayed the approval process for an important cancer treatment.
185290
Not every drug invented in the laboratory is worth developing into a marketable product.
330991
Doctors are missing key information they need to make decisions for cancer patients because some drug companies are not publishing clinical trials.
550498
German drug maker Schering AG was  boosted on Thursday as the U.S. Food and Drug Administration  granted its Bonefos treatment "priority review" for preventing  bone tumors in breast cancer patients.